DRUG · Mapped RxNorm record
Erlotinib
Normalized identity: erlotinibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
NCT01565538
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Pemetrexed
Normalized identity: pemetrexedView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedErlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Lung Cancerverified · MONDO: lung cancer
Interventions
ErlotinibDRUG · verified · RxNorm: erlotinib
PemetrexedDRUG · verified · RxNorm: pemetrexed
Sponsors & collaborators
Si-Yu Wanglead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01565538 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.